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When designing a study for allogeneic hematopoietic stem cell transplantation (HSCT), many choices must be
made, including conditioning regimen, stem cell source, and graft-versus-host disease (GVHD) prevention
method. For each of these, there are a growing number of options, which can be combined into a bewildering
number of possible HSCT protocols. To properly interpret the results of a given strategy and compare them
with others, it is essential that there be agreement on the deﬁnitions and estimation methods of HSCT
endpoints. We report a survey of the recent HSCT literature that conﬁrms the heterogeneity of endpoint
deﬁnitions and estimation methods used. Unfortunately, this heterogeneity may lead to signiﬁcant biases in
the estimates of key endpoints, including nonrelapse mortality, relapse, GVHD, or engraftment. This can
preclude adequate comparisons among studies, even though such comparisons are the major tool with which
to improve HSCT outcome. In the context of our survey, we discuss some of the statistical issues that arise
when dealing with HSCT endpoints and the ramiﬁcations of the choice of endpoint deﬁnition, when the
endpoint occurs in the context of competing risks. Our hope is to generate discussion and motivate a search
for consensus among those who perform transplantations and statisticians.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION and compare the outcomes across subgroups within a given
Allogeneic hematopoietic stem cell transplantation
(HSCT) can deliver a cure for a variety of malignant and
nonmalignanthematologicdisorders, but the simplicityof the
desired outcome belies the great complexity of possible HSCT
outcomes and their relationships. Cure through HSCTmay be
achieved through the cytotoxicity of the conditioning
regimen or through the graft-versus-tumor effect brought
about throughadoptive immunotherapy [1].However, bothof
those effects are also intimately tied to the toxicity ofHSCT. An
increase in conditioning intensity may be associated with
a decreased risk of relapse and graft failure but also with an
increased risk of mortality, and the strength of the graft-
versus-tumor effect is closely tied to the risk and severity of
graft-versus-host disease (GVHD) and its considerable
attendantmorbidity andmortality [2-5]. At present, there are
many ways to perform HSCT, using various options of mye-
loablative conditioning, nonmyeloablative, or reduced-
intensity conditioning (RIC), alongside the traditional bone
marrow and peripheral blood sources of stem cells, umbilical
cord blood transplantation (UCBT), and haploidentical
transplantation. Moreover, there are different methods of
GVHDprophylaxiswithin each of theseHSCT types, leading to
a very large number of possible HSCT strategies. All of those
carry their own distinct pattern of risks and beneﬁts and their
own trade offs between the related outcomes of relapse,
mortality, GVHD, and engraftment.
To optimize HSCT outcome and to learn how to select the
right procedure for the right patients, we must report the
results of well-designed retrospective or prospective studiesedgments on page 864.
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13.01.003study, across arms within a randomized study, or across
studies themselves. Although randomized trials provide
someway to directly compare transplantation strategies over
a set of predeﬁned endpoints, those studies are challenging
to conduct because of the cost and time involved and the
difﬁculty of generating adequate sample sizes within single-
center or oligocenter studies. Randomized studies in HSCT
require extensive planning and large cooperative infra-
structures, which cannot easily keep up with the rapid
development of new HSCT strategies. Many of the changes in
HSCT practice are therefore likely to come from the inter-
pretation of nonrandomized studies. Yet, remarkably, there is
at present no consensus on how to estimate and report such
basic outcomes as engraftment, GVHD, or nonrelapse
mortality (NRM). How canwe hope to compare, for example,
a study of myeloablative conditioning peripheral blood stem
cell transplantation using a new GVHD prevention regimen
and a study of UCBT using a new stem cell expansion
protocol, which likely differ signiﬁcantly in risks of graft
failure, GVHD, relapse, and NRM, if the two studies do not
report those outcomes in the same way?
This is the problem that we consider here. We begin with
a survey of the recent transplantation literature that contains
competing risks data analysis to describe the variability in
endpoint deﬁnition and reporting. We then use some
examples to highlight the challenges and consequences of
the choices that must be made when deﬁning an endpoint in
the presence of competing risks. Some of those choices have
no clearly correct answer, and yet consensus is essential to
move forward. We hope this report can stimulate discussion
and motivate a search for such a consensus.
METHODS
We reviewed all allogeneic transplantation articles published in Biology
of Blood and Marrow Transplantation, Blood, Journal of Clinical Oncology, andTransplantation.
Table 1
Frequencies of Clinical Endpoints Reported and Statistical Methods Used
Endpoint Multivariable Analyses
Performed
Neutrophil/platelet engraftment: 51
Cumulative incidence reported: 25 Cox model used: 2
Competing risk: death
without the engraftment: 14
Competing risks
regression model used: 4
Competing risk: death without the
engraftment or relapse/2nd
transplantation: 2
Performed but method
not stated: 1
Not stated: 9
Median time to engraftment
among engrafted: 16
Mean time to engraftment among
engrafted: 2
Crude proportion: 19
Acute/chronic GVHD: 93
Cumulative incidence reported: 62 Cox model used: 18
Competing risk: death without
GVHD: 26
Competing risks
regression model used: 6
Competing risk: death without GVHD
or relapse/2nd transplantation: 4
Logistic model: 8
Competing risk: death without GVHD,
relapse or graft failure: 1
Performed but method
not stated: 2
Competing risk: death without
GVHD or graft rejection: 2
Not stated: 24
1-KM used: 5
Crude proportion: 46
Relapse and NRM: 96
Cumulative incidence reported: 83 Cox model used:34
Competing risk: relapse for NRM,
NRM for relapse: 52
Competing risks
regression model used: 16
Competing risk: relapse/
2nd transplantation for NRM,
NRM for relapse: 1
Performed but method
not stated: 3
Not stated: 23
1-KM: 8
Crude proportion: 19
Some articles reported both cumulative incidence and crude proportion;
therefore, the sum of the two exceeds the number of articles within each
category.
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with any of the following HSCTclinical outcomes: engraftment, GVHD, NRM,
or relapse. One hundred sixteen articles met this criterion (see Appendix for
the list of these articles). Among them, 86 were retrospective analyses, and
30 were prospective studies; 65 were single-center studies, 19 multicenter
but not registry studies, and 32 were multicenter registry studies.RESULTS
Relapse and NRM
Among the 116 articles in our survey, 96 presented results
for relapse and/or NRM. Of these, 83 presented cumulative
incidences of these events: 52 considered relapse and NRM
as competing risks, 1 considered either relapse or second
transplantation as the competing risk for NRM, and 23 did
not speciﬁcally state what the competing event was or what
method was used; 8 used 1-KM (the complement of the
Kaplan-Meier estimate) to estimate relapse or NRM. In
addition, 19 reported crude proportion (Table 1). Of note,
some articles reported both crude proportion and cumula-
tive incidence of an event. With respect to multivariable
regression analysis, 16 used competing risks regression
models [6,7], 34 used cause-speciﬁc Cox model [8] for
relapse and/or NRM, and 3 did not state which multivariable
regression analysis method was used (Table 1). In most
articles, the deﬁnition of relapse did not explicitly state
whether it included initiation of donor lymphocyte infusion,
repeat HSCT, or graft failure.Graft-versus-Host Disease
The complexity of this topic is reﬂected in the heteroge-
neity of the published literature. Among 116 articles
reviewed, 93 presented results of acute and/or chronic
GVHD. Of these, 62 presented cumulative incidence of
GVHD: 26 used the competing risks data analysis with death
without GVHD as a competing event, 4 considered death or
relapse or second transplantation as competing events, 1
considered death or relapse or graft failure as competing
events, 2 considered death or graft rejection as competing
events, 24 did not state what the competing event was or
what method was used, and 5 used 1-KM without consid-
eration of competing risks. Forty-six reported crude
proportions (Table 1). Again, some articles reported both
cumulative incidences and crude proportions. In addition, 10
articles presented day- 100 cumulative incidence rates of
acute GVHD after RIC HSCT (even though a substantial
number of acute GVHD events occur after 100 days in this
setting). For multivariable regression analysis, 6 articles used
competing risks regression models [6,7], 18 used cause-
speciﬁc Cox models, 8 used logistic regression models, and
2 did not state the method (Table 1).
Engraftment
Fifty-one reviewed articles presented results of neutro-
phil and/or platelet engraftment (deﬁned as absolute
neutrophil count >.5  109/L in the ﬁrst 3 consecutive days
and platelet count >20  109/L in the ﬁrst 7 of consecutive
days without transfusion support, respectively). Of these, 25
reported cumulative incidence of engraftment: 14 consid-
ered death without engraftment as a competing event, 2
considered death or second transplantation or relapse as
competing events, and 9 did not state what the competing
event was or what method was used (Table 1). Sixteen pre-
sented median time to engraftment, and 2 presented mean
time to engraftment among engrafted patients; 19 reported
crude proportions. Only a few articles presented multivari-
able analysis (Table 1).
Perhaps motivated by a number of reports on the impact
of delayed or nonengraftment on survival or GVHD [9-14],
many studies in our survey reported the proportion of
engraftment by a certain time point. However, there was
broad variability on how to deﬁne this time point. Three
studies reported day 28, 5 reported day 30,1 reported day 31,
3 reported day 42, 1 reported day 45, 1 reported day 50, 7
reported day 60, and 3 reported day- 100 neutrophil
engraftment; 1 study reported day 50, 3 reported day 60, 8
reported day 100, and one reported day- 180 platelet
engraftment. Furthermore, two studies of RIC HSCT reported
a range of time for neutrophil and platelet engraftment that
included 0. Those calculations therefore included patients
who did not nadir and whose time to engraftment was
considered to be 0. Because of this, one study reported that
the median time to platelet engraftment was much shorter
than the median time to neutrophil engraftment.
CONSIDERATIONS WHEN DEFINING AN ENDPOINT
To illustrate the impact of the choice of statistical
methods for endpoints with competing risks, we present
a few examples using actual data and highlight the chal-
lenges that arise in statistical analysis of HSCT outcome.
Cumulative Incidence and Competing Events
As shown in our survey, cumulative incidence of an event
in the presence of competing risks can be estimated using
Figure 1. Neutrophil engraftment for 12 patients who received ex vivo, PGE2-
treated double UCBT (PGE2) and 53 who received PGE2-untreated double UCBT
(control). Death is the competing event of neutrophil engraftment.
Figure 2. Cumulative incidence of chronic GVHD with and without excluding
chronic GVHD incidences that occurred after the taper of immunosuppression
among 176 patients who underwent matched unrelated RIC HSCT.
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events as censored observations or using competing risks
method. The difference between these two methods is well
documented in the literature [15-17], and there is broad
agreement that the KM estimator is not an appropriate
choice in the presence of competing risks. However, even
under this agreement, several issues are important: to
appropriately recognize the presence of competing risks, to
appropriately report the results of competing risks analysis,
and to properly select the competing risks.
In the case of relapse and NRM, our survey suggests that
most studies recognize these two events as competing
events, and there is broad agreement that a competing risks
method should be used to calculate the cumulative inci-
dence. However, for engraftment, this is much less clear, and
many studies did not use a competing risks framework when
reporting this endpoint. Because engraftment is particularly
relevant and important in the context of UCBT, where
delayed or nonengraftment may be more frequent and
relevant to survival [10-14], we consider the example from
a UCBT study that compared neutrophil engraftment
between 12 patients who received ex vivo, 16,16-dimethyl-
prostaglandin E2 (PGE2)-treated double UCBT and 53 who
received PGE2-untreated double UCBT [18]. In the PGE2
cohort all patients engrafted, whereas in the control cohort,
there were 2 early deaths without neutrophil engraftment at
days 20 and 24 post transplantation. If the 2 deaths are
included as competing events in the control cohort, the
cumulative incidence of neutrophil engraftment at day 42
(an arbitrary time point) is 100% in the PGE2 and 89% in the
control cohort (P ¼ .04) (Figure 1). If the 2 early deaths in the
control cohort are censored and the 1-KM is used to compare
2 cohorts, the cumulative incidence of neutrophil engraft-
ment at day 42 is 100% in the PGE2 cohort and 94% in the
control cohort (P ¼ .1). Thus, the choice of a statistical
method that is driven by the recognition of competing risks
yields two very different interpretations of the same data,
and judicious choices for analyzing and reporting engraft-
ment will be necessary, especially in UCBT studies.
Another point to note here is that when analyzing an
endpoint using competing risks methods, it is essential that
the cumulative incidences of all competing risks be pre-
sented, as shown in Figure 1. For example, it has beensuggested that the rates of GVHD are lower with UCBT than
with peripheral blood stem cell transplantation [19].
However, UCBT may be associated with an increased risk of
early mortality from delayed engraftment or infection [19].
Because patients who die early from infection are removed
from the at-risk set for GVHD as uncensored observations in
a competing risks analysis and the probability of developing
GVHD for these patients is zero, the rate of GVHDmay appear
low if there is a high early death rate. Therefore, the beneﬁts
and risks of UCBT will only be properly assessed if the inci-
dences of both the event of interest and competing risks are
presented in parallel.
Even when it is agreed that competing risks should be
considered in an endpoint, it is very challenging to agree on
what exactly the competing risks should be. Using GVHD as
an example, death without GVHD is an easy choice. But what
about relapse without GVHD? Many studies have suggested
the interdependent relationship (ie, graft-versus-leukemia
versus GVHD) of these two events [1,20-25]. If relapse
precludes subsequent development of GVHD, it should be
considered as a competing risk to GVHD. Another issue that
arises in reporting GVHD is that the management of post-
HSCT relapse often involves immune manipulation through
accelerated immunosuppression (IS) taper, which clearly
increases the risk of GVHD. Should GVHD incidence occur-
ring after IS taper be counted toward the original
transplantation?
To illustrate the impact of IS taper on GVHD, Figure 2
presents the cumulative incidence of chronic GVHD with
and without considering as GVHD events those that occurred
after the IS taper. One-hundred seventy-six patients who
underwent matched unrelated RIC HSCT between 2006
and 2010 at Dana-Farber Cancer Institute were included.
The 2-year cumulative incidence rate of chronic GVHD is
51% (95% conﬁdence interval, 43%, 59%) if chronic GVHD
developing after the IS taper is counted and 42% (95% E2: 34%,
50%) if not counted. This choice must also consider the
practical consideration that in larger studies (especially
registry studies), information regarding IS taper may not be
easily available. A similar controversy may arise when
considering donor lymphocyte infusion performed for graft
failure if graft failure is not included the in time-to-
progression endpoint. Although there may not be
Figure 3. Cumulative incidence of relapse with different donor types among
1,715 patients from the International Bone Marrow Transplantation Registry
between 1985 and 1991. (Adapted and reprinted with permission from Klein
and Andersen [7].)
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less possible and important so that this endpoint, like others,
may be homogeneously reported.
Multivariable Analysis for Competing Risks Data
Multivariable regression analysis is very useful for iden-
tifying potential prognostic factors or for assessing a prog-
nostic factor of interest after adjusting for other prognostic
factors [17]. If the sample size permits, multivariable
regression analysis allows one to examine whether an
apparent difference between two cumulative incidencesmay
be due to confounding factors.
In our survey, two types of regression methods were used
for multivariable analysis of competing risks data: the Cox
model and a competing risks regression model [6-8]. The
difference between these two models has been extensively
reviewed elsewhere [6,7,17,26,27]. Brieﬂy, the Cox model
tests the effects of covariates on a cause-speciﬁc hazard (eg,
relapse-speciﬁc hazard) treating the competing events (eg,
NRM) as censored observations, whereas the competing
risks regression model [6,7] tests the effects of covariates on
the cumulative incidence of an event directly. Cause-speciﬁc
hazard is the probability of failure due to a speciﬁc cause at
an instantaneous time, given that no failure has occurred up
until that time. Cumulative incidence is the cumulative
probability of an event over time in the presence of
competing events. Thus, testing covariate effects on cause-
speciﬁc hazard is different from testing their effects on the
cumulative incidence of an event directly in the presence of
competing events.
The difference between the two approaches is well
illustrated in the example shown by Klein and Andersen [7].
Using 1,715 patients from the International Bone Marrow
Transplant Registry, they compared relapse and NRM
between patients with different donor types. If a relapse-
speciﬁc multivariable Cox model is used, the hazard ratio
of human leukocyte antigen (HLA)-matched unrelated donor
to HLA-identical sibling donor is 1.01 (P ¼ .94). If a direct
regression model on the cumulative incidence of relapse in
the presence of the competing risk of NRM is used instead,
the hazard ratio is .69 (P ¼ .02) using the Klein and Andersen
model [7] and .73 (P ¼ .004) using the Fine and Gray model
[6], indicating the use of an HLA-matched unrelated donor is
in fact associated with a decreased risk of cumulative inci-
dence of relapse. This difference conforms to the difference
seen in the cumulative incidence curves of relapse (Figure 3,
adapted from Klein and Andersen [7]), with a 5-year cumu-
lative incidence rate of relapse of approximately 18% for
matched unrelated and 25% for matched related donors.
Other multivariable regression analysis methods such as
additive or multistate models have also been proposed
[27,28] but are beyond the scope of this article.
Because the two methods are designed to address
different questions, the Cox and competing risks regression
models may yield different results, as in the example above.
Despite this difference in model formulation between two
approaches, our survey suggests some controversy remains
over which model should be chosen for standard use in the
analysis of competing risks data. As in other areas discussed
previously, there may not be a right and a wrong choice, and
practically the two methods often give similar results; yet it
is important to understand the consequences of the choice of
a tool on the interpretation of data. Further discussion is
needed as to which model should be adopted for standard
use. To this end, consideration should also be given for otherexisting models or for development of new models as an
alternative.CONCLUSIONS
Statistical analyses of HSCT outcome face unique
challenges because many clinical endpoints depend on graft-
versus-tumor and GVHD, two events that are immunologi-
cally intertwined but of diametrically opposite clinical
consequences. For this reason, competing risks methodology
is an essential part of endpoint estimation in HSCT research.
However, the choice of the competing events for an endpoint
of interest are far from clear and yet have signiﬁcant impli-
cations on the estimate itself. Our survey highlights the great
variability in both endpoint deﬁnition and estimation
methods in the recent HSCT literature. The most commonly
recognized competing risks are relapse and NRM, whereas
engraftment is rarely considered in a competing risks
framework. Our ﬁndings underscore the need for a
consensus approach, much as consensus was needed to
develop useful clinical deﬁnitions for chronic GVHD [29-31].
Unless such a consensus is reached, comparisons of results
across HSCT studies or study arms will remain difﬁcult. It is
also critical that, even in the absence of consensus, the
chosen endpoint deﬁnitions and estimation methods be
described in enough detail in published studies for their
results to be properly interpreted. Our survey suggests that
those details are often omitted.
Given the challenges associated with conducting
randomized controlled trials in HSCT and the rapid parallel
developments in all aspects of HSCT, including conditioning
regimen optimization, development of alternative stem cell
sources, ex vivo stem cell processing, GVHD prophylaxis, and
relapse prevention, we need to be able to compare results
across all salient HSCT endpoints, and for this, we need
a common language. Ultimately, the freedom to deﬁne new
endpoints may have been an instrument of progress in
promoting a better understanding of HSCT and the devel-
opment of new HSCT techniques, but we may be paying the
cost of this freedom if we cannot properly interpret their
results.
H.T. Kim, P. Armand / Biol Blood Marrow Transplant 19 (2013) 860e866864ACKNOWLEDGMENTS
The authors are deeply indebted to Dr. Mary Horowitz for
her critical review and also gratefully acknowledge the
support of Drs. Robert Gray, Robert Soiffer, Joseph Antin, and
Jerome Ritz for their valuable comments on the manuscript.
Financial disclosure: Supported by NIAID U19 AI29530,
and NCI PO1 CA142106. P.A. is a recipient of an American
Society of Hematology Scholar Award and an ASCO/Conquer
Cancer Foundation Career Development Award.
Authorship Statement: H.T.K. designed the study and
performed the data analysis. H.T.K. and P.A. wrote the
manuscript.REFERENCES
1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reac-
tions after bone marrow transplantation. Blood. 1990;75:555-562.
2. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow trans-
plantation in patients with acute myeloid leukemia in ﬁrst remission:
a randomized trial of two irradiation regimens. Blood. 1990;76:
1867-1871.
3. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hemato-
poietic progenitor cells with purine analog-containing chemotherapy:
harnessing graft-versus-leukemia without myeloablative therapy.
Blood. 1997;89:4531-4536.
4. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell
transplantation and cell therapy as an alternative to conventional bone
marrow transplantation with lethal cytoreduction for the treatment of
malignant and nonmalignant hematologic diseases. Blood. 1998;91:
756-763.
5. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irra-
diation (TBI) and ﬂudarabine followed by hematopoietic cell trans-
plantation (HCT) from HLA-matched or mismatched unrelated donors
and postgrafting immunosuppression with cyclosporine and myco-
phenolate mofetil (MMF) can induce durable complete chimerism and
sustained remissions in patients with hematological diseases. Blood.
2003;101:1620-1629.
6. Fine JP, Gray RJ. A proportional hazards model for the subdistribution
of a competing risk. J Am Stat Assoc. 1999;94:496-509.
7. Klein JP, Andersen PK. Regression modeling of competing risks data
based on pseudovalues of the cumulative incidence function. Biomet-
rics. 2005;61:223-229.
8. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall;
1984. p. 91-110.
9. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after
unrelated-donor bone marrow transplantation: a report from the
national marrow donor program. Blood. 2000;96:4096-4102.
10. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic
cell transplantation for hematologic malignancy: relative risks and
beneﬁts of double umbilical cord blood. Blood. 2010;116:4693-4699.
11. Ramírez P, Brunstein CG, Miller B, et al. Delayed platelet recovery after
allogeneic transplantation: a predictor of increased treatment-related
mortality and poorer survival. Bone Marrow Transplant. 2011;46:
981-986.
12. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated
donor umbilical cord blood in 102 patients with malignant and
nonmalignant diseases: inﬂuence of CD34 cell dose and HLA disparity
on treatment-related mortality and survival. Blood. 2002;100:
1611-1618.13. Gluckman E, Rocha V, Arcese W, et al. Factors associated with
outcomes of unrelated cord blood transplant: guidelines for donor
choice. Exp Hematol. 2004;32:397-407.
14. Terakura S, Azuma E, Murata M, et al. Hematopoietic engraftment in
recipients of unrelated donor umbilical cord blood is affected by the
CD34þ and CD8þ cell doses. Biol Blood Marrow Transplant. 2007;13:
822-830.
15. Kalbﬂeisch JD, Prentice RL. The statistical analysis of failure time data.
New York: John Wiley & Sons; 2002.
16. Gray RJ. A class of K-sample tests for comparing the cumulative inci-
dence of a competing risk. Ann Stat. 1988;16:1140-1154.
17. Kim HT. Cumulative incidence in a competing risks setting and
competing risks regression analysis. Clin Cancer Res. 2007;13:559-565.
18. Cutler CS, Shoemaker D, Ballen KK, et al. FT1050 (16,16-dimethyl
prostaglandin E2)-enhanced umbilical cord blood accelerates hemato-
poietic engraftment after reduced intensity conditioning and double
umbilical cord blood transplantation. Blood (ASH Annual Meeting
Abstracts). 2011;118:653.
19. Eapen M, Rocha V, Sanz G, et al., Center for International Blood and
Marrow Transplant Research; Acute Leukemia Working Party Eurocord
(the European Group for Blood Marrow Transplantation); National
Cord Blood Program of the New York Blood Center. Effect of graft
source on unrelated donor haemopoietic stem-cell transplantation in
adults with acute leukaemia: a retrospective analysis. Lancet Oncol.
2010;11:653-660.
20. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute
leukemia with T-cell depleted stem cells from related donors with one
fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.
21. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-
identical transplants in leukemia. Blood. 1991;78:2120-2130.
22. Ringdén O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia
effect using matched unrelated donors is not superior to HLA-
identical siblings for hematopoietic stem cell transplantation. Blood.
2009;113:3110-3118.
23. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects
after allogeneic hematopoietic cell transplantation with non-
myeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.
24. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-
matched unrelated or matched sibling donor transplantation for acute
myeloid leukemia in ﬁrst remission with unfavorable cytogenetics at
diagnosis. Blood. 2010;116:1839-1848.
25. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center
for International Blood and Marrow Transplant Research analysis.
Blood. 2011;117:6714-6720 [Erratum in: Blood 2011 Dec 22;118(26):
6992.].
26. Logan BR, Zhang MJ, Klein JP. Regression models for hazard rates versus
cumulative incidence probabilities in hematopoietic cell trans-
plantation data. Biol Blood Marrow Transplant. 2006;12(1 suppl 1):
107-112.
27. Klein JP. Modelling competing risks in cancer studies. Stat Med. 2006;
25:1015-1034.
28. Andersen PK, Abildstrom SZ, Rosthøj S. Competing risks as a multi-
state model. Stat Methods Med Res. 2002;11:203-215.
29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference
on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
30. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. I. Diagnosis and Staging Working Group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
31. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. VI. Design of Clinical Trials Working Group
report. Biol Blood Marrow Transplant. 2006;12:491-505.
H.T. Kim, P. Armand / Biol Blood Marrow Transplant 19 (2013) 860e866 865APPENDIX. LIST OF ARTICLES REVIEWEDJournal Year of Publication Volume Number Page Number Lead Author
BBMT 2010 16 7 927-936 Goyal et al.
BBMT 2010 16 7 937-947 Perkins et al.
BBMT 2010 16 7 957-966 Ferra et al.
BBMT 2010 16 7 967-975 Deschler et al.
BBMT 2010 16 7 976-984 Glezerman et al.
BBMT 2010 16 7 1025-1031 Ballen et al.
BBMT 2010 16 8 1099-1106 Schriber et al.
BBMT 2010 16 8 1107-1114 Rizzieri et al.
BBMT 2010 16 8 1122-1129 Efebera et al.
BBMT 2010 16 8 1155-1161 Tomblyn et al.
BBMT 2010 16 9 1231-1236 McAvoy et al.
BBMT 2010 16 9 1237-1244 Verneris et al.
BBMT 2010 16 9 1257-1264 Stringaris et al.
BBMT 2010 16 9 1272-1281 Lin et al.
BBMT 2010 16 9 1309-1314 Cantoni et al.
BBMT 2010 16 9 1315-1323 Blin et al.
BBMT 2010 16 10 1370-1381 Larsen et al.
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BBMT 2010 16 10 1442-1450 Navarro et al.
BBMT 2010 16 11 1463-1466 Rotta et al.
BBMT 2010 16 11 1567-1575 Liu et al.
BBMT 2010 16 11 1582-1588 Kang et al.
BBMT 2010 16 11 1589-1595 Sanz et al.
BBMT 2010 16 12 1693-1699 Levine et al.
BBMT 2010 16 12 1700-1706 Newell et al.
BBMT 2010 16 12 1718-1727 Wermke et al.
BBMT 2010 16 12 1728-1737 Sairaﬁ et al.
BBMT 2010 16 12 1738-1746 Hill et al.
BBMT 2011 17 1 78-85 Latour et al.
BBMT 2011 17 1 86-92 Grifﬁth et al.
BBMT 2011 17 1 93-100 Vigouroux et al.
BBMT 2011 17 1 101-108 Lee et al.
BBMT 2011 17 1 109-116 Barlogis et al.
BBMT 2011 17 1 133-140 Boehm et al.
BBMT 2011 17 2 239-248 Pidala et al.
BBMT 2011 17 2 265-269 Rosenzwajg et al.
BBMT 2011 17 3 341-350 Nemecek et al.
BBMT 2011 17 3 356-364 Oran et al.
BBMT 2011 17 3 374-383 Klyuchnikov et al.
BBMT 2011 17 3 384-393 Dabaja et al.
BBMT 2011 17 3 393-400 Kagoya et al.
BBMT 2011 17 3 401-411 Kurosawa et al.
BBMT 2011 17 4 542-549 Xiao et al.
BBMT 2011 17 4 550-557 Pastore et al.
BBMT 2011 17 4 558-565 Bashey et al.
BBMT 2011 17 4 574-585 Torres et al.
BBMT 2011 17 5 640-648 Valcarcel et al.
BBMT 2011 17 5 649-656 Huang et al.
BBMT 2011 17 5 710-716 Solh et al.
BBMT 2011 17 5 717-722 AlZahrani et al.
BBMT 2011 17 6 821-830 Wang et al.
BBMT 2011 17 6 831-840 Burke et al.
BBMT 2011 17 6 841-851 Waki et al.
BBMT 2011 17 6 867-874 Kanda et al.
BBMT 2011 17 6 875-884 Novitzky et al.
BBMT 2011 17 6 885-892 Woofrey et al.
BBMT 2011 17 6 893-900 Andersson et al.
BBMT 2011 17 6 901-907 Cappoletta et al.
BBMT 2011 17 6 908-915 Eissa et al.
BBMT 2011 17 6 916-922 Rosenbeck et al.
BBMT 2011 17 6 923-929 Ciurea et al.
Blood 2010 115 26 5412-5417 MacMilan et al.
Blood 2010 116 18 3572-3581 Alchalby et al.
Blood 2010 116 10 1795-1802 Bethge et al.
Blood 2010 116 22 4693-4699 Brunstein et al.
Blood 2010 116 16 3080-3088 Chakraverty et al.
Blood 2010 116 14 2411-2419 Cooley et al.
Blood 2010 116 14 2438-2447 Dreger et al.
Blood 2010 116 1 122-128 Giebel et al.
Blood 2010 116 10 1655-1662 Gratama et al.
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Blood 2010 116 11 1839-1848 Gupta et al.
Blood 2010 116 11 1849-1856 Herr et al.
Blood 2010 116 8 1369-1376 Hishizawa et al.
Blood 2010 116 15 2644-2650 Mann et al.
Blood 2010 116 3 366-374 Marks et al.
Blood 2010 116 26 5824-5831 Marsh et al.
Blood 2010 116 22 4439-4443 Mohty et al.
Blood 2010 116 20 4368-4375 Nishiwaki et al.
Blood 2010 116 19 4007-4015 Shaw et al.
Blood 2010 116 4 649-652 Takagi et al.
Blood 2010 116 15 2839-2846 Takanashi et al.
Blood 2010 116 24 5111-5118 Wingard et al.
Blood 2011 117 24 6714-6720 Arora et al.
Blood 2011 117 19 5261-5263 Bacahnova et al.
Blood 2011 117 26 7174-7184 Bornhauser et al.
Blood 2011 117 1 53-62 Booth et al.
Blood 2011 117 3 1061-1070 Brunstein et al.
Blood 2011 117 11 3214-3219 Flowers et al.
Blood 2011 117 24 6721-6727 Giaccone et al.
Blood 2011 117 13 3641-3647 Jabbour et al.
Blood 2011 117 11 3032-3040 Jiang et al.
Blood 2011 117 1 309-315 Rosenthal et al.
Blood 2011 117 5 1745-1750 Sabloff et al.
Blood 2011 117 17 4642-4650 Schulz et al.
Blood 2011 117 16 4367-4375 Slatter et al.
Blood 2011 117 9 2728-2734 Smith et al.
Blood 2011 117 23 6375-6382 Socie et al.
Blood 2011 117 25 6963-6970 Soiffer et al.
JCO 2010 28 22 3644-3652 Bassan et al.
JCO 2010 28 20 3344-3351 Casper et al.
JCO 2010 28 29 4492-4499 Duarte et al.
JCO 2010 28 23 3730-3738 Duval et al.
JCO 2010 28 33 4924-4934 Kyriakou et al.
JCO 2010 28 30 4642-4648 Schlenk et al.
JCO 2010 28 23 3695-3700 Thomson et al.
JCO 2011 29 2 214-222 Dreyer et al.
JCO 2011 29 7 805-813 Horan et al.
JCO 2011 29 10 1342-1348 Kampen et al.
JCO 2011 29 3 294-302 Parmar et al.
JCO 2011 29 8 971-978 Peggs et al.
JCO 2011 29 9 1190-1197 Walter et al.
JCO 2011 29 16 2230-2239 Wingard et al.
NEJM 2010 363 22 2091-2101 Gooley et al.
BBMT indicates Biology of Blood and Marrow Transplantation; JCO, Journal of Clinical Oncology; NEJM: New England Journal of Medicine.
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